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Background: Prevention of alveolar bone destruction is a
clinical challenge in periodontal disease treatment. The recep-
tor activator of nuclear factor-kappa B ligand (RANKL) inhib-
itor osteoprotegerin (OPG) inhibits osteoclastogenesis and
suppresses bone resorption.
Methods: To study the effects of RANKL inhibition on alve-
olar bone loss, an experimental ligature-inducedmodel of peri-
odontitis was used. A total of 32 rats were administered human
OPG-Fc fusion protein (10 mg/kg) or vehicle by subcutane-
ous delivery twice weekly for 6 weeks. Negative or positive
controls received no treatment or disease through vehicle
delivery, respectively. Biopsies were harvested after 3 and 6
weeks, and mandibulae were evaluated by microcomputed to-
mography (mCT) and histology. Serum levels of human OPG-
Fc and tartrate-resistant acid phosphatase-5b (TRAP-5b)
were measured throughout the study by enzyme-linked immu-
nosorbent assay (ELISA). Statistical analyses included analy-
sis of variance (ANOVA) and Tukey tests.
Results: Human OPG-Fc was detected in the sera of OPG-
Fc–treated animals by 3 days and throughout the study. Se-
rum TRAP-5b was sharply decreased by OPG-Fc treatment
soon after OPG-Fc delivery and remained low for the observa-
tion period. Significant preservation of alveolar bone volume
was observed among OPG-Fc–treated animals compared to
the controls at weeks 3 and 6 (P <0.05). Descriptive histology
revealed that OPG-Fc significantly suppressed osteoclast sur-
face area at the alveolar crest.
Conclusion: Systemic delivery of OPG-Fc inhibits alveolar
bone resorption in experimental periodontitis, suggesting that
RANKL inhibition may represent an important therapeutic
strategy for the prevention of progressive alveolar bone loss.
J Periodontol 2007;78:1300-1308.
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P
eriodontitis is a destructive disease
that targets tooth-supporting struc-
tures through complex and mul-
tifactorial pathogenic processes. It is
triggered by an interaction between bac-
terial components of tooth-associated
biofilms and host response mechanisms.1
Alveolar bone destruction, a hallmark of
periodontitis progression and one of the
major causes of tooth loss in humans, is
mediated by the host immune and in-
flammatory response to microbial chal-
lenge. In recent decades, studies on
cellular and molecular mechanisms of
bone loss in periodontitis have sug-
gested that the use of host modulation
agents is an important adjunctive ther-
apy to antimicrobial strategies.2
The discovery of the receptor activa-
tor of nuclear factor-kappa B (RANK)/
RANK ligand (RANKL)/osteoprotegerin
(OPG) axis has improved the knowledge
of bone metabolism regulation and cre-
ated a new field for the study of treatment
of bone destruction–related diseases, in-
cluding rheumatoid arthritis, metastatic
bone cancer, and periodontal disease.
The RANKL/RANK interaction is needed
for differentiation and maturation of oste-
oclast precursor cells to activated osteo-
clasts and for the survival of mature
osteoclasts. Stimulatory factors such
as hormones (vitamin D3, parathyroid
hormone, parathyroid hormone–related
protein), cytokines (interleukin-1, -6, -11,
and -17), growth factors (tumor necrosis
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factor-a and bone morphogenetic protein-2), and other
molecules (prostaglandin E2, cytoplasmic domain-
40L, and glucocorticoid), upregulate the expression
of the RANKL gene in osteoblasts/stromal cells.3,4 Se-
quentially, RANKL triggers osteoclastogenesis through
RANK on preosteoclast cells. Acting as a soluble de-
coy receptor, OPG binds to RANKL and inhibits oste-
oclast development. Several studies have shown the
opposing effects of RANKL and OPG on bone turn-
over. Genetic ablation of RANKL in mice results in os-
teopetrosis,5,6 whereas genetic deletion of OPG in
mice results in high bone turnover and severe osteopo-
rosis.7-9 Moreover, several factors initiating bone re-
sorption not only upregulate RANKL expression but
also inhibit OPG expression in osteoblasts/stromal
cells.3,10 Upregulation of RANKL has also been seen
in inflamed periodontal tissues, indicating that RANKL
participates in the processes of periodontal tissue
destruction.11,12 On the other hand, the RANKL/OPG
ratio is increased in periodontitis compared to non-
diseased individuals, suggesting that this molecular
interaction may be important in modulating local
bone loss. The RANKL/OPG ratio was found to be sig-
nificantly increased in gingival crevicular fluid (GCF)
of patients with periodontitis compared to healthy
individuals.13
As a therapeutic drug for preventing bone loss,
OPG has recently been evaluated in preclinical stud-
ies relating to estrogen deficiency, skeletal tumors,
and specific cancers,6,14-17 as well as in clinical trials
involving postmenopausal women, juvenile Paget’s
disease, and lytic bone disease associated with can-
cer.18-20 All of these results showed that OPG has sig-
nificant effects on the inhibition of bone loss.
The use of OPG as an inhibitor of alveolar bone de-
struction in periodontal disease was studied in mice
orally infected with Actinobacillus actinomycetenco-
mitans. Inhibition of RANKL function with OPG treat-
ment significantly reduced the number of osteoclasts
and alveolar bone loss.21,22
The aim of this study was to evaluate the thera-
peutic effects of human recombinant OPG fusion
protein (rhOPG-Fc) on preventing alveolar bone loss
in an acute model of ligature-induced experimental




All animal experiment procedures in this study were
approved by the University of Michigan Committee
of Use and Care of Animals.
To explore the OPG-Fc effects on alveolar bone
loss in experimental periodontitis, 32 male Sprague-
Dawley ratsi (weight: 250 to 300 g) were divided into
four experimental groups: group A, animals receiving
no treatment (normal healthy control or NT); group B,
animals receiving rhOPG-Fc¶ subcutaneous adminis-
tration twice weekly (OPG-treated healthy controls or
OPG alone group); group C, animals exposed to dis-
ease induction and OPG subcutaneous injection twice
weekly (OPG-treated diseased animals); and group
D, animals exposed to disease induction and subcuta-
neous vehicle administration twice weekly (vehicle-
treated diseased animals). There were four animals
at each designated time point for each group. Block
biopsies were harvested at 3 and 6 weeks after disease
induction and/or OPG administration.
To further study the in vivo pharmacokinetics of
injected rhOPG-Fc, four normal healthy animals
received a single subcutaneous administration of
rhOPG-Fc, and serum rhOPG-Fc was measured by
an enzyme-linked immunosorbent assay (ELISA) at
designated time points.
Experimental Periodontal Disease Induction and
OPG Administration
Sprague-Dawley rats were anesthetized using inhala-
tion anesthesia with isoflurane. 3/0 cotton ligatures
were placed bilaterally into the gingival sulci of the
mandibular first molar teeth. The ligatures were eval-
uated twice weekly, gently displaced apically into the
gingival sulci to ensure a subgingival position, and re-
placed when necessary. The use of ligatures for induc-
tion of experimental periodontitis elicits rapid alveolar
bone destruction through two combined mecha-
nisms: an inflammatory process induced by increased
microbial biofilm formation around the cervix of the
teeth and an acute physical irritation factor as a con-
sequence of the subgingival placement of the ligature,
typically leading to the loss of approximately one-half
of the bone support over a period of 3 to 6 weeks. The
rhOPG-Fc was administered subcutaneously at a
dose of 10 mg/kg animal body weight twice a week
during 3 or 6 weeks.
In Vivo Pharmacokinetics of Injected rhOPG-Fc
To study the pharmacokinetics of a single subcutane-
ous injection of rhOPG-Fc at a dose of 10 mg/kg rat
body weight, ;600 ml blood was drawn from the tail
vein of each animal at 0, 0.5, 1, 3, 7, 14, and 21 days.
The samples were transferred into serum separator
tubes# and centrifuged at 4,000 rpm for 10 minutes
at 4C. The supernatants were collected and stored
at -80C until needed for analysis. The content of
serum rhOPG-Fc was measured using a commer-
cially available human OPG ELISA kit.** The ELISA
i Harlan, Indianapolis, IN.
¶ Amgen, Thousand Oaks, CA.
# Becton Dickinson, Franklin Lakes, NY.
** American Laboratory, Windham, NH.
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procedures were performed according to the manu-
facturer’s instructions.
Serum rhOPG-Fc and Tartrate-Resistant Acid
Phosphatase-5b (TRAP-5b) Measurements During
Disease Progression
To measure rhOPG-Fc serum concentration after
twice weekly OPG injections as a part of the experi-
mental protocol, the blood from the tail vein was
drawn at 0, 1.5, 3, 4.5, and 6 weeks, and serum was
collected according to the methods outlined above.
Serum rhOPG-Fc and TRAP-5b levels were mea-
sured by commercially available human OPG†† and
rat TRAP-5b‡‡ ELISA kits, respectively. The ELISA
procedures were performed according to the manu-
facturer’s instructions.
OPG-Fc Clearance From Bone
Young male rats were injected once (intravenously
[IV]) with rhOPG-Fc at 5 mg/kg. Groups of rats (N =
6) were sacrificed at various times after treatment.
Histologic sections of the proximal tibial metaphysis
were subjected to immunohistochemistry analysis
for human Fc (immunoglobulin [IgG]1). Deparaffi-
nized 4-mm sections were blocked,§§ and sections
were incubated with rabbit anti-human IgGii at
1:4,000 for 1 hour. Antibody was detected by biotiny-
lated goat anti-rabbit IgG¶¶ and followed with alkaline
phosphatase ABC complex.## The reaction was visu-
alized with red alkaline phosphatase substrate.*** All
sections were counterstained with hematoxylin.
Microcomputed Tomography (mCT) Scanning
and Analysis
In vitro mCT provides high qualification and accurate
quantification of mineralized tissues such as alveolar
bone and teeth.23 Each mandibular specimen was
scanned and reconstructed at 18 · 18 · 18-mm voxels
using a mCT system.††† A three-dimensional (3-D)
volume viewer and analyzer software‡‡‡ were used
as the tool for both 3-D and 2-D visualization and
quantification.
Linear and volumetric analyses were based on a
previously developed methodology.23 In brief, verti-
cal, linear bone loss was obtained by measuring the
distance from the cemento-enamel junction (CEJ) to
the alveolar bone crest or to the base of the alveolar
intrabony defect at the mesial surface of the mandib-
ular first molar teeth. In terms of 3-D analysis, the
most mesial root of the first molar (m-M1), the second
molar (m-M2), the roof of the furcation, and root
apex of M1 were used as reproducible landmarks for
estimation of alveolar bone loss. Two-dimensional re-
gions of interest (ROIs) were drawn at regular intervals
(average, eight data slices) on a coronal view and re-
constructed as a 3-D structure to quantify volumetric
parameters, bone volume fraction (BVF), and bone
mineral density (BMD; mg/cc). The measurements
of coded specimens were made by two independent,
calibrated examiners (JAC and CHP).
Histology and TRAP Immunostaining
TRAP immunohistochemical staining was performed
to identify and quantify osteoclast-like cells. Harvested
mandibulae were fixed for 48 hours in 10% neutral-
buffered formalin, decalcified with 10% EDTA for
2 weeks, embedded in paraffin, and cut into 4- to
5-mm-thick sections. TRAP immunohistochemical
staining was performed on these sections with
anti-TRAP antibody§§§ and an immunostaining kitiii
to identify osteoclast-like cells covering the bone
surface.
Images of coded specimens were captured using a
microscope¶¶¶ fitted with a digital camera### for anal-
ysis using software.**** The length of the bone sur-
face covered by osteoclasts in a 0.5-mm coronal
ROI at the alveolar crestal bone was measured by a
single calibrated examiner (QJ).
Statistical Analysis
The differences among groups for linear and volumet-
ric bone loss measurements, serum level of rhOPG-Fc
and TRAP5b, and osteoclast-like cell surface area
were statistically assessed by one-way analysis of
variation (ANOVA) with Tukey multiple comparison
post hoc test using a statistical software package.††††
The level of significance was set as P £0.05.
RESULTS
In Vivo rhOPG-Fc Pharmacokinetics
The healthy animals receiving a single injection of
rhOPG-Fc displayed an increase in serum rhOPG
within 12 hours after administration, reaching a max-
imal level of 23.2 – 5.1 mg/ml at 3 days. Serum rhOPG
subsequently decreased to 1.2 – 1.4 mg/ml at 14 days
and 0.125 – 0.152 mg/ml at 21 days (Fig. 1).
OPG-Fc Clearance From the Vasculature of
Rat Bone
After IV injection of human OPG-Fc, OPG primarily
was circulated in blood rather than in the bone matrix.
At 12 hours after administration, the peak level of
serum OPG was reached and subsequently decreased
†† ALPCO Diagnostics, Salem, NH.
‡‡ RatTRAP Assay, SBA Sciences, Oulu, Finland.
§§ CAS Block, Zymed Laboratories, San Francisco, CA.
ii Jackson Laboratories, West Grove, PA.
¶¶ Vector Laboratories, Burlingame, CA.
## Vector Laboratories.
*** Vector Laboratories.
††† GE Healthcare, London, ON.
‡‡‡ Microview Analysis+ v.2.1.2 software, GE Healthcare, London, ON.
§§§ sc-30833, Santa Cruz Biotechnology, Santa Cruz, CA.
iii Goat ABC Staining System kit (sc-2023), Santa Cruz Biotechnology.
¶¶¶ Eclipse 50i, Nikon, Melville, NY.
### Digital Sight DS U1, Nikon.
**** Image Pro Plus, Media Cybernetics, Silver Spring, MD.
†††† GraphPad Prism version 4.00, GraphPad Software, San Diego, CA.
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over time. At 20 days, no circulating OPG was found in
the blood vessels of bone (Fig. 1B).
Serum rhOPG-Fc and TRAP-5b Levels During
Disease Progression
Figure 2 shows serum rhOPG and TRAP-5b levels af-
ter rhOPG-Fc administration twice a week. By 10 days
after injection, the serum rhOPG levels of OPG-treated
healthy and diseased animals rose sharply to 31.6 –
12.3 mg/ml and 34 – 28.4 mg/ml, respectively. The se-
rum OPG within the OPG-treated diseased animals
steadily increased over 6 weeks, whereas the serum
OPG level within the OPG-treated healthy control
showed no changes through 6 weeks. At 6 weeks, the
OPG levels in OPG-treated diseased animals were sig-
nificantly greater than the OPG-treated
healthy controls (P <0.01). Compared
to the vehicle-treated diseased animals,
OPG levels of OPG-treated animals were
significantly higher at each designated
time point (P <0.01; Fig. 2A). The endog-
enous OPG levels in normal healthy con-
trols and vehicle-treated animals were
low (data not shown).
The changes in serum TRAP-5b levels
within the rhOPG-Fc–injected and non-
rhOPG-Fc–injected animals are shown
in Fig. 2B. During the first 10 days after
rhOPG-Fc administration, serum TRAP-
5b levels in rhOPG-Fc–injected animals
sharply declined to undetectable levels,
whereas TRAP-5b levels in non-rhOPG-
Fc–treated animals decreased only
slightly or remained unchanged. After
10 days, the serum TRAP-5b levels of
rhOPG-Fc–treated animals sustained
lower levels, but the serum TRAP-5b
levels of non-rhOPG-Fc–treated animals
slowly decreased. At all time points ex-
cept baseline, the TRAP-5b levels in
rhOPG-Fc–delivered animals were sig-
nificantly lower than those of non-
rhOPG-Fc–injected animals (P <0.01).
No other groups displayed differences
in TRAP-5b levels (Fig. 2B).
mCT Analysis
The alveolar bone crest at 3 weeks
within the vehicle-treated animals sig-
nificantly decreased from 0.83 – 0.1
mm (no treatment group) to 1.28 –
0.2 mm, which indicates that ;50%
bone loss was elicited by experimental
periodontitis (Figs. 3 and 4A). At 6
weeks, the bone crest within the vehicle-
treated animals also decreased from
1.05 – 0.1 mm (no treatment group) to 1.4 – 0.2
mm, resulting in 40% bone loss. Significant differ-
ences of CEJ to bone crest (C-C) distance were only
found in the vehicle-treated animals compared to the
other three groups.
For volumetric measurements at the 3-week time
point, experimental periodontitis resulted in the low-
est BVF in the vehicle-treated animals compared to
the other three groups, whereas the OPG-treated
healthy controls had the highest BVF (Fig. 4B). At 6
weeks, the vehicle-treated animals again showed
the lowest BVF among all groups, whereas the OPG
administration groups had significantly higher BVF
compared to the no treatment group (Fig. 4B). In
terms of BMD, the OPG-treated healthy controls
Figure 1.
In vivo rhOPG-Fc pharmacokinetics after a single subcutaneous administration. A) The
maximum level of serum rhOPG was seen at 3 days after administration. Serum rhOPG
decreased within 14 days. At 21 days after injection, the delivered rhOPG was eliminated
completely. Bars represent SDs. *P <0.01 compared to baseline. B) Human OPG
immunostaining in the proximal tibial metaphysis. Young male rats received a single infusion
IV with human OPG-Fc at 5 mg/kg. The delivered human OPG circulated primarily in the
blood rather than integrating into the bone matrix. The highest serum level of administered
human OPG appeared 12 hours after IV infusion, and the serum OPG was eliminated over
time. N = 6 animals per group. Bars = 25 mm. RBCs = red blood cells; h = hours; d = days.
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showed the highest BMD, whereas the vehicle-treated
animals had the lowest BMD at 3 weeks. At 6 weeks,
the vehicle-treated animals had the lowest BMD, and
there was a significant difference found between the
normal healthy and OPG-treated healthy controls
(Fig. 4C).
TRAP Immunostaining and Osteoclast Surface
Analysis of Alveolar Bone
Histologic analysis of four animals in each group at 3
and 6 weeks revealed increases in TRAP-stained oste-
oclasts in the region of the alveolar bone crest in dis-
eased vehicle-treated animals compared to healthy
controls (Fig. 3). In accordance with histologic obser-
vations, the coverage of osteoclasts at the alveolar
bone crest showed that osteoclasts in vehicle-treated
animals occupied ;50% the surface of the alveolar
bone within the coronal 0.5 mm, which was the high-
est of all the groups (Fig. 5). In contrast, very few
TRAP-stained osteoclasts were observed in OPG-
treated animals. OPG treatment of healthy animals
was associated with a virtual absence of osteoclasts
along the alveolar bone crest, whereas OPG treatment
of diseased animals resulted in a three-fold reduction
in osteoclast surface compared to vehicle-treated
diseased animals (Fig. 5). This level of suppression
reduced osteoclast surface area to levels found in
normal healthy animals. In addition, compared to
the linear bone loss measurement, the bone loss is
related to the osteoclast surface area covering the
bone (Fig. 5). The vehicle-treated diseased animals
showed the highest osteoclast coverage and the most
extensive bone loss.
DISCUSSION
To the best of our knowledge, this study showed for
the first time a protective effect of OPG in an acute
model of experimental periodontitis. To evaluate the
effect of human OPG on the alveolar bone changes
of rats at physiologic and pathologic conditions, it is
imperative to show adequate systemic drug exposure.
Human proteins including OPG-Fc can be immuno-
genic in rats, which would lead to rapid clearance
of the drug and inadequate drug exposure. Single-
dose pharmacokinetic assessment of human OPG-Fc
revealed a Cmax at day 3, which indicates that twice-
weekly administrations would ensure maximal expo-
sure. After twice-weekly OPG administration, >30 mg/
ml serum OPG concentration was obtained and sus-
tained, which proved to be the effective serum OPG
level to reduce the number of osteoclasts and
inhibit bone loss (Figs. 4 and 5). This serum OPG con-
centration is similar to the serum OPG level (26.1 –
5.2 mg/ml) found to be optimal for preventing bone re-
sorption as previously reported by Capparelli et al.24
However, inflammation may influence in vivo OPG
degradation. Serum OPG levels in OPG-treated dis-
eased animals remained elevated and were two-fold
higher at 6 weeks compared to the OPG alone group,
which may result from the decrease of the OPG
degradation-related enzymes elicited by periodontal
inflammation.
Three-dimensional images of the mandibular mo-
lars generated by mCT were used to evaluate the pre-
ventive effects of OPG on alveolar bone loss. Linear
measurements indicated that the vehicle-treated ani-
mals displayed higher levels of bone loss compared
to other groups, whereas both groups receiving OPG
injection showed similar bone levels compared to
the healthy controls. This suggests that OPG inhibits
Figure 2.
A) Serum rhOPG levels after twice weekly subcutaneous
administration. Higher serum rhOPG levels were seen in OPG delivery
groups, whereas rhOPG levels remained almost undetectable in
vehicle-treated animals. At 6 weeks, the serum rhOPG levels between
the OPG + disease and the OPG alone groups were statistically
significantly different (†P <0.05). *P <0.05 compared to the vehicle
group. Bars represent SDs. B) Serum TRAP-5b levels after repeated
subcutaneous administration. Serum TRAP-5b levels in rhOPG-injected
animals decreased sharply at 10 days and remained very low until
6 weeks, whereas the serum TRAP-5b levels in non-rhOPG-injected
animals gradually declined. Except at baseline, the TRAP-5b levels in
non-rhOPG-treated groups were significantly higher than those in
rhOPG-injected groups. *P <0.05 compared to non-rhOPG-treated
groups. Bars represent SDs. N = 4 animals per group. Veh = vehicle.
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alveolar bone loss induced by experimental periodon-
titis. Protective effects of OPG on alveolar bone
resorption were previously shown in an A. actinomy-
cetencomitans oral inoculation-induced periodontitis
model21,22 and a tooth biomechanical movement
model (our unpublished data). In addi-
tion, measurements of the BVF, repre-
senting the percentage of bone volume
of the delineated region, were statistically
lower in the vehicle-treated animals
compared to all other groups at 3 and
6 weeks, showing that experimental
periodontitis stimulated more bone loss
in the absence of OPG administration.
Therefore, OPG seems to rescue not
only alveolar bone height but also loss
of BMD induced by experimental peri-
odontitis.
To evaluate the effects of OPG on the
osteoclast formation in alveolar bone,
the coronal 0.5 mm of bone crest at
the mesial surface of the first molars
was chosen because those areas are un-
der the direct influence of experimental
periodontitis and most subject to osteo-
clast formation. Our results showed that
the vehicle-treated diseased animals
showed a higher percentage of bone
surface covered by TRAP-positive oste-
oclasts than the other groups at 3 weeks,
whereas the OPG-treated diseased ani-
mals had the same bone surface cover-
age of TRAP-positive osteoclasts as
normal rats, which suggests that OPG
inhibits osteoclast formation. Similar re-
sults were also seen in the application of
OPG to situations of increased osteo-
clastic bone resorption, which results
from certain types of cancers, rheuma-
toid arthritis.25 or A. actinomycetenco-
mitans inoculation.21,22 In addition,
OPG administration also causes a de-
crease in serum TRAP-5b, a marker of
osteoclastic resorption.26 This indicates
that the reduction of osteoclast number
elicited by OPG application results in a
decrease of TRAP-5b originating from
osteoclasts.
A potentially important advantage for
clinical application of OPG is the lack
of incorporation of OPG into bone ma-
trix, as shown in Fig. 1B. As a result,
its effects on osteoclasts and bone re-
modeling are fully reversible.24,27 This
mechanism of action could have bene-
fits versus agents such as bisphospho-
nates, which are directly incorporated into bone matrix
and thus have poor reversibility. Bisphosphonates
have shown efficacy in patients with osteoporosis,
Paget’s disease, and tumor bone disease,28 and these
agents have shown potent effects as host-modulating
Figure 3.
OPG-Fc blocks alveolar bone loss in experimental periodontitis. Left panels show the mesial
view of mCT 3-D images of mandibular first molars of each group at 3 weeks. The vehicle +
disease group shows the greatest degree of bone loss. Right panels show the histology of the
alveolar bone at the mesial side of mandibular first molars of each group at 3 weeks (TRAP
immunostaining; magnification, ·200). TRAP-positive osteoclasts are stained brown. Higher
numbers of positively stained osteoclasts were noted on the surface of alveolar bone in the
vehicle + disease groups. Few osteoclasts were seen at the alveolar bone crest in the OPG +
disease group. Furthermore, no positively stained cells were found in the OPG alone group.
Blue arrows demarcate the CEJ. Yellow arrows indicate the alveolar bone crest. Black
arrows indicate positive TRAP-stained osteoclast-like cells. Veh = vehicle; B = bone crest;
D = dentin. N = 4 animals per group.
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agents for periodontal disease treatment.29-31 How-
ever, bisphosphonate therapy has also been asso-
ciated with osteonecrosis of the jaw (ONJ),32,33 a
condition described by the persistent exposure of
necrotic bone in the oral cavity. The etiology of bis-
phosphonate-related ONJ is poorly understood, but
periodontal disease has been the most common co-
morbidity in bisphosphonate-treated patients with
ONJ.32 In cancer patients on IV bisphosphonates,
the relative riskofdevelopingONJ increases markedly
after several years of bisphosphonate use.33 Bis-
phosphonate accumulation in bone matrix is a direct
function of the total administered dose,34 and the
skeletal uptake of bisphosphonates is not reduced
by prior high-dose bisphosphonate therapy.35 These
observations suggest that skeletal accumulation of
Figure 4.
OPG-Fc blocks alveolar bone loss in experimental periodontitis as measured by linear and volumetric mCT. A) The linear measurement of the distance
from the CEJ to alveolar bone crest at the mesial roots of mandibular first molars in each group. The greatest difference was seen in the vehicle +
disease group at both 3 and 6 weeks, whereas there was no significant difference among other groups. B) The fractions of bone volume versus the
total volume surrounded by the superficial surfaces of five roots of first mandibular molar. At 3 and 6 weeks, the vehicle + disease group showed the
smallest BVF, whereas the OPG alone group displayed the greatest BVF. No significant difference was found between the no treatment and OPG +
disease groups. C) BMD for the regions surrounded by the superficial surfaces of all roots of first mandibular molars of each group. At 3 and 6 weeks,
BMD in the vehicle + disease group was the lowest, whereas the OPG alone group displayed the highest BMD. No significant difference was found
between no treatment and OPG + disease groups. N = 4 animals per group. *P <0.05; †P <0.01; bars represent SDs. Veh = vehicle.
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bisphosphonates continues despite the ability of these
agents to markedly suppress bone turnover. Because
periodontitis can be a chronic disease, it may be inap-
propriate to use long-term bisphosphonates for the
prevention of alveolar bone loss until the etiology of
bisphosphonate-related ONJ is elucidated.
CONCLUSIONS
In this study, OPG revealed strong preventive effects
on alveolar bone loss in experimental periodontitis,
thus showing promising therapeutic potential of OPG
for treatment of periodontal disease. Future studies
will need to examine the ability of OPG to block pro-
gression of established disease and humanapplication.
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